The needs are so pressing among patients living with rare and devastating diseases and as such, calling for more pragmatic approach
In our interactions with patients and health care practitioners across China, we have realized that there exists a significant gap between the therapies accessible to them in China and those available in developed markets. As such, we have decided that the first step in our endeavor shall be sourcing and introducing the transformative therapies from the more developed markets. At the current stage, we focus primarily on both commercial-stage and late-clinical-stage therapies. We introduce them via either in-licensing or early access programs or a combination of both.